ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 957

Long-Term Evaluation of NT-Probnp Levels in Ankylosing Spondylitis Patients Under TNF Blockers: A Marker of Persistent Disease Activity?

Debora Russo1, Carla G.S. Saad2, Ana C.M. Ribeiro1, Cláudia Goldeinstein-Schainberg2, Percival D Sampaio-Barros2, Celio R. Gonçalves2, Eloisa Bonfá1 and Julio C. B. Moraes2, 1Rheumatology Division, University of Sao Paulo, Sao Paulo, Brazil, 2Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS) and anti-TNF therapy, NT-proBNP

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondyloarthropathies and Psoriatic Arthritis II - Novel Treatments Psoriatic Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose N-terminal pro-brain natriuretic peptide (NT-proBNP) is a strong marker of cardiovascular risk with recent evidence that short-term inflammation control reduces its levels in ankylosing spondylitis (AS) patients under TNF blockers. There are no data regarding long-term NT-proBNP assessment in AS patients using TNF blockers. Therefore, we evaluated longitudinally NT-proBNP in AS patients pre- and post-long-term TNF blockage therapy and its possible association with sustained disease activity.

Methods Forty-eight consecutive AS patients (NY criteria) without previous/current cardiovascular disease or systolic myocardial dysfunction in echocardiography, who were eligible to anti-TNF therapy, were prospectively enrolled. All patients received TNF blockers (infliximab, adalimumab or etanercept) and they were evaluated for circulating NT-proBNP levels, clinical and laboratory parameters of disease activity including BASDAI, ASDAS, ESR and CRP, traditional cardiovascular risk factors including blood pressure, body mass index, waist circumference and treatment data at baseline (BL), 12 (12M) and 24 months-after (24M). Statistical analysis included: ANOVA test or Friedman test to observe differences at BL, 12M and 24M evaluations; Mann-Whitney test or t-test to observe differences between patients with inactive/moderate active and high/very high disease activity at 24M; and multivariable linear regression analysis. All analyses used significance level of 0.05.

Results At BL, all patients had active AS. NT-proBNP levels had a median (IQR) of 23.5(8-53.7) pg/ml and 6.2% had high levels without any evidence of cardiac systolic dysfucntion. Multiple linear regression analysis revealed that this peptide, at BL, was independently correlated with ESR (p=0.003) and pulse pressure (p=0.025). Longitudinal evaluation after 12M and 24M showed that all disease parameters improved (p<0.05) and NT-proBNP levels significantly reduced [19(5-38) pg/mL and 14(5-35) pg/mL respectively, p=0.011]. Of note, NT-proBNP levels were higher in patients with persistent high/very high disease activity (ASDAS-CRP>2.1) at 24M (p<0.001) compared to inactive/ moderate active disease patients (ASDAS-CRP<2.1) at same time. Reinforcing this finding, this difference between these groups was present also at BL (p=0.024) and 12M (p=0.03).  Further comparison of BL parameters of patients that persists with ASDAS-CRP>2.1 at 24M identified that these patients are older (44.6±12.7 vs. 35±9.9 years-old, p=0.007), more often female (53.3% vs. 21.2%, p=0.043) and they have higher body mass index (29±5.0 vs. 25.7±4.7 kg/m2, p=0.028), BASDAI (6.6±2.4 vs.5.1±1.9, p=0.02) and ASDAS-ESR (3.9±1.0 vs.3.1±0.9, p=0.006) at BL.  Multivariate analysis did not show any independent factor related to higher ASDAS-CRP at 24M.

Conclusion The novel finding of sustained higher long-term NT-proBNP levels in AS patients with persistent high/very high disease activity during anti-TNF therapy and without systolic alteration suggest that this parameter may reflect longitudinal inflammatory status. (ClinicalTrials.govnumber:NCT01072058).


Disclosure:

D. Russo,
None;

C. G. S. Saad,
None;

A. C. M. Ribeiro,
None;

C. Goldeinstein-Schainberg,
None;

P. D. Sampaio-Barros,
None;

C. R. Gonçalves,
None;

E. Bonfá,
None;

J. C. B. Moraes,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-evaluation-of-nt-probnp-levels-in-ankylosing-spondylitis-patients-under-tnf-blockers-a-marker-of-persistent-disease-activity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology